found this post on ymb copied from facebook Jesus6

New Post Public Reply Private Reply Replies (1) Message Board
crazyjogger925 Riztheinvestor #114775
695
found this post on ymb copied from facebook


Jesus6 minutes ago
Fund Raising

Dear Fellow Shareholders,
My name is A. Balikcioglu. I am a double board-certified gastroenterologist and internist by the American Board of Internal Medicine and Gastroenterology. I am affiliated with multiple hospitals in the New York area, including Mt. Sinai Hospital and Montefiore Medical Center. I have been in practice for over 20 years and I am qualified in the cutting-edge developments of my field.

I am writing to you as a long shareholder of CytoDyn (CYDY). I am a steadfast believer in the tremendous potential of the company’s drug, Leronlimab, a monoclonal antibody CCR5 receptor antagonist, to be used as a platform drug for variety of indications. I believe that this is a revolutionary drug and is positioned to be the next generation of medication. If the company is successful in securing US FDA approval of any current studies, including HIV BLA, many lives will be saved and tremendous value will be created for the company’s stockholders.

Over the past months, there have been scare-mongering hysterics about the company that are substantially unfounded and aimed to distract stockholders from the facts. There are a lot of people and big players who are actively working against CytoDyn by manipulating its stock through the dissemination of inaccurate and fake news about the company. Big pharma knows and understands the value of CytoDyn’s medication once it gets FDA approval. They want this late-stage biotechnology company to fail so that they can take over CytoDyn for almost nothing.

Leronlimad continues to meet expectations and it is just a matter of time before it receives US FDA approval. The effects of market volatility, speculation, and malicious manipulation by a lot of people and companies — which stand to gain if CytoDyn fails — has disproportionately affected the company’s stocks (CYDY). I strongly believe that this a short-term phase and is not representative of the actual financial value of CytoDyn with the success of its revolutionary drug. The company just needs some time to get this medication FDA approved. But, the malicious manipulation that has caused the stock to drop is affecting the company and paralyzing it from doing anything. Any company or individual who, directly or indirectly, try to prevent this drug from being approved should be criminally charged because they are preventing patients from getting life-saving treatment and putting their own financial gain over the lives of these patients.

The biggest challenge we are dealing with right now is this short term drop of CYDY value which threatens the long-term viability and success of the company’s operations and Leronlimab’s achievement of its full potential. As a fellow long position shareholder, I am reaching out to you to proactively ensure that our investments and belief in the potential of the company to create significant value for its shareholders is not upended. In my opinion, we have two choices on how to deal with this short-term drop in the CYDY stock value: we either allow the company to go bankrupt, or we actively save the company by raising enough funds for the company’s operations to continue.

We need to bond together as a group to capitalize on the significant opportunities that can be gained from Leronlimab’s potential to unlock substantial value for all stockholders. I propose that each of us, shareholders, raise enough fund to keep the company afloat during this challenging period. We can discuss further details on how we can do it in a group Zoom meeting. For example, if 3000 shareholders directly invest on average $20,000.00, we will be able to easily raise $60,000,000.00 to ensure the financial stability of CytoDyn and to propel its growth. This money will have 2 effects: 1) the company will have sufficient capital to function and operate for at least a year; 2) it will ease the concerns of more shareholders about the stability of the company, causing them to buy more stocks and invest further.

Of course, we will make sure that the money we will raise would be controlled by a small group directly chosen by us through a serious selection of individuals, who are professionally knowledgeable about finance and biotech companies, such as CPAs, lawyers, and investment professionals. The money could also be provided directly to CytoDyn in exchange for future stocks or financial interests. After we raise an “X” amount of money, we can meet with the executives of CytoDyn to discuss the procedures and terms before releasing it to the company.

If you have any doubts about my credentials, please feel free to Google my information.

The contents of this letter and my recommendations are solely my own thoughts and solution. They do not represent the opinions of any hospitals I am affiliated with. I did not take part, nor do I have any access to any of the research done in connection with CytoDyn’s drug.

Sincerely,
A. Balikcioglu, M.D.

(Copied from Facebook)

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 75

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 7

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 25

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
1031 Specialists Takes Tax Deferral to Public TV

Updated Category News Views 100

A tax rule most people ignore is getting a television spotlight. 1031 Specialists says it will appear on All Access with Andy Garcia, an educational series distributed to Public Television stations nationwide, to explain the 1031 exchange and its role in real estate investing. That is a sensible bit of exposure for a niche business built around a topic investors tend to...

Continue Reading
Fire-Resistant Lubricants Offer a Quiet Value Shift

Updated Category News Views 67

Hydraulic fluid is not the sort of product that gets anyone pounding the table, and that is precisely why this little industrial pocket deserves a hard look. The fire-resistant lubricants market is estimated at $2.35 billion in 2026 and projected to reach $2.83 billion by 2031, implying a 3.74% compound annual growth rate. That is not a rocket ship. It is a slow-moving,...

Continue Reading
Avenir Nears 19.99% Grid Stake After Falcon West Resource

Updated Category News Views 35

Falcon West finally put enough geological meat on the bone to make Avenir reach for its wallet. Avenir Minerals expects to buy 29,388,127 Grid Metals common shares on or about November 30, 2026, taking its non-diluted position to 19.99%. That number is not accidental. It is the usual Canadian strategic-investor ceiling before the conversation starts getting considerably...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 36

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
Morrison Tests Abu Dhabi as Its Next Capital Hub

Updated Category News Views 60

Abu Dhabi keeps collecting infrastructure managers the way a strong port collects ships: because the money, the policy ambition, and the projects are all converging there. Morrison’s decision to establish an office in ADGM is not some chest-thumping headline about instant deal flow. It is a practical move by a firm with nearly four decades behind it and more than US$35...

Continue Reading
NEWWAVE Turns 15 and Chases a Bigger Tech Partner Role

Updated Category News Views 97

Fifteen years is about when an outsourced engineering shop has to prove it can be more than extra hands on a keyboard. NEWWAVE’s new identity and “Trusted Technology Partner” positioning are an attempt to make that jump: from carrying out software work to helping clients decide what work ought to be done, then sticking around after launch. It is a sensible ambition,...

Continue Reading

Top 5 Most Recently Viewed Articles

DocGo Inc. Faces Legal Scrutiny Amid Allegations of Misconduct

Updated Category News Views 303

Continuation of Investigation into DocGo Inc. Former Louisiana Attorney General Charles C. Foti, Jr., Esq., is continuing the investigation into DocGo Inc. The firm Kahn Swick & Foti, LLC (KSF), where Foti serves as a partner, is actively pursuing key information related to the conduct of the company’s officers and directors. This scrutiny comes in response to serious...

Continue Reading
Comprehensive Metabolic Panel Testing Market Growth Insights

Updated Category News Views 171

Overview of the Comprehensive Metabolic Panel Testing Market The Comprehensive Metabolic Panel (CMP) testing market is witnessing significant growth, driven by an increasing focus on preventive healthcare and early disease detection. This sector is estimated to expand remarkably in the upcoming years, projected to reach USD 24.48 billion by 2032 with a robust compound...

Continue Reading
Celebrating Future Legal Talents with Ándale Scholarship 2025

Updated Category News Views 244

Two Future Legal Leaders Awarded 2025 Ándale Scholarship At a recent ceremony that brought together the finest minds in the legal profession, two bright law students were honored with the esteemed Ándale Scholarship for the year 2025. This award, conferred by Gastelum Attorneys, is a symbol of recognition for outstanding achievement and potential in the field of law....

Continue Reading
Arkstone and Neslab Join Forces to Innovate Healthcare Solutions

Updated Category News Views 330

Arkstone Partners with Neslab to Transform Healthcare in Peru Arkstone Medical Solutions has forged a pioneering partnership with Neslab, a prominent medical technology firm based in Peru. This collaboration aims to broaden access to precision-guided treatments for infectious diseases across the nation. By leveraging cutting-edge antimicrobial stewardship tools and...

Continue Reading
Opportunity for Investors to Explore NeueHealth's Status

Updated Category News Views 155

Investors Encouraged to Join the Investigation of NeueHealth The Schall Law Firm, a leading national shareholder rights litigation firm, is currently investigating claims on behalf of investors in NeueHealth, Inc. (“NeueHealth” or “the Company”) (NYSE: NEUE). The focus of this investigation is to determine whether the directors and management of NeueHealth have...

Continue Reading